Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif. , June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing... Read More

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 AM ET in New York, NY 46 th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11,... Read More

Haorui’s established footprint brings HiFi sequencing to new customers including hospital labs and regional blood centers MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution... Read More

MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The... Read More

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million $19.0 million Consumable revenue $20.1 million $16.0 million Service and other revenue $6.0 million $3.8 million Revio™ systems 12 28 Vega™ systems 28 — Annualized Revio... Read More

MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in... Read More

MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Dennis Lo and colleagues at the The Chinese University of Hong Kong... Read More

MENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), a global initiative to prevent Alzheimer’s disease and improve brain health, today announced that PacBio (NASDAQ: PACB), a leader in high-quality, highly-accurate long-read sequencing platforms, will be a technology partner to its North African Dementia Registry (NADR) project. Spearheaded by DAC, this... Read More

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Preliminary Q1 2025 Q1 2024 Revenue $36.9 million $38.8 million Instrument... Read More

MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 342,432 shares of PacBio common stock to the Company’s recently hired Chief Financial Officer, Jim Gibson, under the Pacific... Read More

MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company’s new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley’s most iconic and... Read More

MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes... Read More

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. A live webcast of the event can be accessed at the company’s investors page at... Read More

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a... Read More

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period. Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024... Read More

MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice... Read More

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/ . Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)... Read More

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive... Read More

MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics . The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition , showcases how researchers leveraged PacBio’s advanced sequencing solutions, including the... Read More

MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS) at the University of Saskatchewan (USask) as the first Revio PacBio Certified Service Provider (CSP) in Canada. Known for its leadership in animal, microbial and plant genomics, GIFS offers PacBio’s HiFi sequencing... Read More

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics . The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare... Read More

Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio ® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year... Read More

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay... Read More

MENLO PARK, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, has delivered its first Vega systems to Berry Genomics as part of an early access agreement announced in 2022. Under the terms of the original agreement, Berry Genomics will develop and optimize its targeted assays to support carrier, prenatal, and newborn screening programs in China... Read More

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. A live webcast of the event can be accessed at the company’s investors page at... Read More

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 5:00 PM ET in Rancho Palos Verdes, CA Wolfe Research Healthcare Conference on Tuesday, November 19, 2024,... Read More

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50%... Read More

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 million in the prior-year period. Instrument revenue of $16.8 million compared with $34.7 million in the prior-year period. Instrument revenue in the third quarter of 2024 included 22 Revio™ sequencing... Read More

MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the Vega™ system , the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality of the Revio system, PacBio’s high-throughput long-read... Read More

BOSTON , Oct. 30, 2024 /PRNewswire/ -- Volta Labs™ , a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the partnership between Volta Labs and PacBio. Volta Labs is partnering with PacBio to offer walk-away automation for PacBio library prep, enabling labs to... Read More

MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system . The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind... Read More

MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and applications, thereby... Read More

SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's advanced sequencing technologies, including the innovative Onso short-read... Read More

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/ . Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen... Read More

SINGAPORE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the Agency for Science, Technology, and Research (A*STAR), and Macrogen, today announced the opening of a state-of-the-art joint laboratory at A*STAR Genome Institute of Singapore (A*STAR GIS) in Singapore. This new facility, located on Level 5 of the Genome... Read More

MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of PacBio common stock to a... Read More

SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read... Read More

MENLO PARK, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly advance male infertility and rare disease research. By deploying PacBio’s Revio HiFi sequencing system, researchers at Münster will obtain... Read More

MENLO PARK, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:05 p.m. Eastern Time. The event will be live-streamed on the company's investors page at... Read More

MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 million in the prior-year period. Instrument revenue of $14.7 million compared with $29.9 million in the prior-year period. Instrument revenue in the second quarter of 2024 included 24 Revio™ sequencing systems.... Read More

SINGAPORE, Aug. 05, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that Precision Health Research, Singapore (PRECISE) has chosen the Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project. This initiative aims to generate the largest long-read sequencing dataset in Southeast Asia, marking a significant advancement for... Read More

MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific community. Novogene is a leading provider of genomic services and bioinformatics... Read More

MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/ . Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen... Read More

Companies Form Expert Working Group to Introduce Essential Tools for AAV Development and Research Professionals SAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio , the provider of advanced computational life sciences technology and PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a range of new initiatives aimed at advancing and unifying the AAV industry.... Read More

Consortium Delivers Publicly Available Datasets that Enrich Detection of Rare and Novel Genetic Variants for Advances in Human Disease Research MENLO PARK, Calif. , June 10, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing (CoLoRS), today announced the launch of the first publicly... Read More

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif. , May 15, 2024 /PRNewswire/ -- Ambry Genetics , a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies'... Read More

MENLO PARK, Calif. , May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024 . First quarter results: Revenue of $38.8 million compared with $38.9 million in the prior-year period. Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. Instrument revenue in the first quarter of 2024 included 28 Revio TM sequencing systems.... Read More

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results Preliminary revenue of $38.8 million , roughly flat compared with $38.9 million in the... Read More

HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif. , March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the... Read More

MENLO PARK, Calif. , March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock... Read More

HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological... Read More

MENLO PARK, Calif. , Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 , at 1:30 PM ET in Boston, MA Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024... Read More

MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. Fourth quarter results Revenue of $58.4 million , a 113% increase compared with $27.4 million in the prior-year period. Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. Consumables revenue of $18.9 million compared with... Read More

ATLANTA , Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBash 11th Annual Event Experience Awards. The award recognizes the outstanding use of technology to create an immersive and engaging event experience for PacBio (NASDAQ: PACB) a pioneering leader in the Biotechnology industry. The... Read More

New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System MENLO PARK, Calif. , Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system. With these kits, PacBio takes another leap forward in the... Read More

MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024 , at 5:00 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Thursday, February 15, 2024 , at 5:00 pm ET ( 2:00 pm PT )... Read More

Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria MENLO PARK, Calif. , Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read... Read More

Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing grows and increased capacity from the Revio system drives sample elasticity MENLO PARK, Calif. , Jan. 8, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,... Read More

MENLO PARK, Calif. , Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 , at 1:30 PM PT ( 4:30 PM ET ) in San Francisco, California . A live webcast of the event can be accessed at the company's investors page at... Read More

MENLO PARK, Calif. , Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein , Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023 . "I would like to thank David for his dedication to PacBio since he joined the Board in 2012," said Christian Henry , President and... Read More

MENLO PARK, Calif. , Nov. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023 , at 2:00 PM ET in New York, NY Piper Sandler 35th Annual Healthcare... Read More

Consortium Aims to Share Best Practices and Increase our Understanding of Genetic Disease MENLO PARK, Calif. , Nov. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium. This global consortium brings together researchers from 15 leading genomics research institutions across 11 countries to study the... Read More

Partnerships Maximize Value of HiFi Data and Complete the Full End-to-End Workflow for PacBio Customers. MENLO PARK, Calif. , Nov. 1, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the addition of two tertiary analysis partners to PacBio Compatible. Geneyx and Golden Helix will enable PacBio customers to leverage PacBio HiFi data for... Read More

Building on the MAS-Seq Concatenation Method, These Three New Kits can Significantly Increase Throughput in RNA Applications MENLO PARK, Calif. , Oct. 31, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S... Read More

MENLO PARK, Calif. , Oct. 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023 . Third quarter results Revenue of $55.7 million , a 72% increase compared with $32.3 million in the prior-year period. Instrument revenue of $34.7 million compared with $11.4 million in the prior-year period. Instrument revenue in the third quarter of 2023 included revenue... Read More

Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif. , Oct. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023 . Mr. Meline was most recently the Chief Financial Officer of Moderna, Inc., a... Read More

MENLO PARK, Calif. , Oct. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Monday, October 30, 2023 , at 4:30 pm ET ( 1:30 pm PT ) Listen... Read More

PacBio WGS Variant Pipeline Will Bring Standardization to PacBio HiFi Data Analysis MENLO PARK, Calif. , Oct. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis. The new software pipeline... Read More

New Program Expands Access to PacBio's Highly Accurate Sequencing Systems by Providing Flexible Financing MENLO PARK, Calif. , Sept. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PacBio Capital, a program that offers customers the ability to lease PacBio sequencing systems – Revio, Onso and Sequel IIe – easily and cost-effectively.... Read More

Hamilton, Integra, Revvity, and Tecan Join PacBio Compatible to Offer Verified Automated Library Prep Workflows for Whole Genome Sequencing MENLO PARK, Calif. , Sept. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples... Read More

MENLO PARK, Calif. , Aug. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: UBS MedTech, Tools and Genomics Summit 2023 on Wednesday, August 16, 2023 , at 4:00 PM PT in Dana Point, CA Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday,... Read More

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn. , Aug. 7, 2023 /PRNewswire/ -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a research collaboration... Read More

MENLO PARK, Calif. , Aug. 4, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units ("RSUs") covering 184,700 shares of PacBio common stock to fourteen... Read More

MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023 . Second quarter results Revenue of $47.6 million , a 34% increase compared with $35.5 million in the prior year-period. Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II/IIe systems in the... Read More

PacBio will Combine Apton's Proprietary Sequencing Technology With its Highly Accurate Sequencing by Binding Chemistry to Develop a High-Throughput Sequencer Designed to Deliver Billions of Reads per Flow Cell MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into an agreement to acquire Apton Biosystems,... Read More

The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso... Read More

MENLO PARK, Calif. , July 19, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023 , at 5:00 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Wednesday, August 2, 2023 , at 5:00 pm ET ( 2:00 pm PT ) Listen... Read More

Bioscientia Acquires Multiple Revio Sequencing Systems to Revolutionize Rare Disease Research by Sequencing Thousands of Long-Read Human Genomes Annually MENLO PARK, Calif. , June 28, 2023 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced that Bioscientia is using its Revio long-read sequencing systems to expand its genomics research projects and sequence... Read More

MENLO PARK, Calif. , June 26, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (" PacBio ") (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% Convertible Senior Notes due 2028 (the " 2028 Notes "), pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 (the " New... Read More

Collaboration Aims to Show Utility and Cost Effectiveness of HiFi Sequencing in Clinical Research Settings, Using Revio Systems MENLO PARK, Calif. , June 14, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions today announced a clinical research study with Radboud University Medical Center (Radboudumc) to explore genetic causes of rare and genetic diseases.... Read More

Current Member, Jay Shendure , is Appointed Chair MENLO PARK, Calif. , May 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Olga Troyanskaya , Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board (SAB) and Jay... Read More

MENLO PARK, Calif. , May 25, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences: Bernstein's 39th Annual Strategic Decisions Conference on Thursday, June 1, 2023 , at 2:30 PM ET in New York, NY Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June... Read More

MENLO PARK, Calif. , May 3, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada . PacBio management is scheduled to participate in a fireside chat on Wednesday, May 10th, 2023 , at 9:20 am Pacific Time . Interested parties may access a live... Read More

MENLO PARK, Calif. , May 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023 . First quarter results Revenue of $38.9 million , a 17% increase compared with $33.2 million in the prior year period. Shipped 38 sequencing systems in the first quarter, including 32 Revio systems and 6 Sequel IIe systems. Instrument revenue of $20.7 million compared with $15.6... Read More

MENLO PARK, Calif. , April 18, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Tuesday, May 2, 2023 at 4:30 pm ET ( 1:30 pm PT ) Listen live via... Read More

Kits Combine the Power of HiFi Sequencing and Nanobind Technology to Optimize Sample Preparation Workflows for High Volume Customers MENLO Park, Calif. , April 5, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of its new... Read More

MENLO PARK, Calif. , March 28, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced new workflows developed with global agriculture company, Corteva Agriscience that enable high throughput plant and microbial genome sequencing. This collaboration, which originated at the Advances in Genome Biology and Technology (AGBT) Agricultural meeting last... Read More

Paraphase Enables Researchers to Analyze Genes That are Critically Relevant but Hard to Genotype MENLO PARK, Calif. , March 14, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy. The new computational tool, named "Paraphase," enables variant calling, copy number... Read More

Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000 MENLO PARK, Calif. , March 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the first customer... Read More

MENLO PARK, Calif. , Feb. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in Cowen's 43rd Annual Health Care Conference in Boston, Massachusetts . PacBio management is scheduled to participate in a fireside chat on Tuesday, March 7th at 12:50 PM ET . Interested parties may access a live and archived... Read More

MENLO PARK, Calif. , Feb. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2022 . Fourth quarter results Received record orders in the fourth quarter, including orders for 96 instruments, which included orders for 76 Revio systems from 43 customers across 13 countries and representing a broad set of applications. Revenue of $27.4 million , a... Read More

End-to-End Solutions Planned to Support Key Customer Applications With Increased Cost Flexibility on Long-Read Sequencing Systems MENLO PARK, Calif. , Feb. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of a program intended to expand Multiplexed Arrays Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and... Read More

MENLO PARK, Calif. , Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Thursday, February 16, 2023 at 4:30 pm ET ( 1:30... Read More

MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public... Read More

MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock, at the public offering price, less... Read More

MENLO PARK, Calif. , Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022." Nature Methods had recognized the impact of long-read sequencing in a variety of groundbreaking studies, including those leveraging PacBio technology from the Vertebrate Genome Project,... Read More

PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022 , making it the most successful... Read More

MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo , Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese... Read More

MENLO PARK, Calif. , Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference: Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023 , at approximately 5:15 PM PT . Company presentation and Q&A session on... Read More

Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif. , Dec. 6, 2022 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the C hildren's R are D isease C ohorts Initiative (CRDC) at Boston Children's Hospital. Boston Children's Hospital researchers... Read More